Evidence map›Paper›PMID 28560632›Full record

ArticleJournal of neurovirology2017

Improvements in brain and behavior following eradication of hepatitis C.

Taylor Kuhn, Philip Sayegh, Jacob D Jones, Jason Smith, Manoj K Sarma, A Ragin, Elyse J Singer, M Albert Thomas, April D Thames, Steven A Castellon and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of neurovirology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Taylor KuhnDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 760 Westwood Plaza, #C8-749, Los Angeles, CA, 90095, USA. tkuhn@mednet.ucla.edu.
Philip SayeghDepartment of Psychology, UCLA, 2191 Franz Hall, Box 951563, Los Angeles, CA, 90095, USA.
Jacob D JonesDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 760 Westwood Plaza, #C8-749, Los Angeles, CA, 90095, USA.
Jason SmithPsychology Service, Veterans Administration (VA) Greater Los Angeles Healthcare System, 11301 Wilshire Blvd., Los Angeles, CA, 90073, USA.
Manoj K SarmaDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 760 Westwood Plaza, #C8-749, Los Angeles, CA, 90095, USA.
A RaginDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 760 Westwood Plaza, #C8-749, Los Angeles, CA, 90095, USA.
Elyse J SingerDepartment of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
M Albert ThomasDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 760 Westwood Plaza, #C8-749, Los Angeles, CA, 90095, USA.
April D ThamesDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 760 Westwood Plaza, #C8-749, Los Angeles, CA, 90095, USA.
Steven A CastellonDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 760 Westwood Plaza, #C8-749, Los Angeles, CA, 90095, USA.
Charles H HinkinDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 760 Westwood Plaza, #C8-749, Los Angeles, CA, 90095, USA.
University of California, Los Angeles · USVA Greater Los Angeles Healthcare System · US

Funding

NATIONAL NEUROLOGICAL AIDS BANKU24MH100929 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 2013 to 2023
$12.5M
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV TherapyR01MH083553 · NIMH · BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE · PI HINKIN, CHARLES H · 2008 to 2012
$3.0M
NEUROSPYCHOLOGY AIDS FELLOWSHIPT32MH019535 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HINKIN, CHARLES H · 1991 to 2017
$2.3M
NIMH NIH HHS R01 MH083553NIMH NIH HHS T32 MH019535NIMH NIH HHS U24 MH100929
6 · The paper itself

Abstract

Despite recent advances in treatment, hepatitis C remains a significant public health problem. The hepatitis C virus (HCV) is known to infiltrate the brain, yet findings from studies on associated neurocognitive and neuropathological changes are mixed. Furthermore, it remains unclear if HCV eradication improves HCV-associated neurological compromise. This study examined the longitudinal relationship between neurocognitive and neurophysiologic markers among healthy HCV- controls and HCV+ adults following successful HCV eradication. We hypothesized that neurocognitive outcomes following treatment would be related to both improved cognition and white matter integrity. Participants included 57 HCV+ participants who successfully cleared the virus at the end of treatment (sustained virologic responders [SVRs]) and 22 HCV- controls. Participants underwent neuropsychological testing and, for a nested subset of participants, neuroimaging (diffusion tensor imaging) at baseline and 12 weeks following completion of HCV therapy. Contrary to expectation, group-level longitudinal analyses did not reveal significant improvement in neurocognitive performance in the SVRs compared to the control group. However, a subgroup of SVRs demonstrated a significant improvement in cognition relative to controls, which was related to improved white matter integrity. Indeed, neuroimaging data revealed beneficial effects associated with clearing the virus, particularly in the posterior corona radiata and the superior longitudinal fasciculus. Findings suggest that a subgroup of HCV+ patients experienced improvements in cognitive functioning following eradication of HCV, which appears related to positive changes in white matter integrity. Future research should examine whether any additional improvements in neurocognition and white matter integrity among SVRs occur with longer follow-up periods.

Indexed as

AdultAnisotropyBrainCase-Control StudiesCognitionDiffusion Tensor ImagingExecutive FunctionFemaleHepacivirusHepatitis C, ChronicHumansMaleMemoryMiddle AgedNeuropsychological TestsWhite MatterDiffusion tensor imagingHepatitis C virusNeurocognitionNeuropathologySustained virologic responseWhite matter integrity

Identifiers

PMID28560632
PMCPMC5623101
OpenAlexW2617971870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.